Progyny, Inc. (NASDAQ:PGNY) Forecasted to Earn FY2025 Earnings of $0.62 Per Share

Progyny, Inc. (NASDAQ:PGNY) – Research analysts at Leerink Partnrs decreased their FY2025 earnings estimates for shares of Progyny in a research note issued on Wednesday, September 18th. Leerink Partnrs analyst M. Cherny now forecasts that the company will post earnings per share of $0.62 for the year, down from their prior forecast of $0.86. Leerink Partnrs has a “Hold” rating on the stock. The consensus estimate for Progyny’s current full-year earnings is $0.64 per share. Leerink Partnrs also issued estimates for Progyny’s FY2027 earnings at $1.41 EPS.

Progyny (NASDAQ:PGNY) last announced its quarterly earnings results on Tuesday, August 6th. The company reported $0.17 earnings per share for the quarter, meeting the consensus estimate of $0.17. The business had revenue of $304.09 million during the quarter, compared to analysts’ expectations of $305.32 million. Progyny had a net margin of 5.54% and a return on equity of 11.97%. The firm’s revenue for the quarter was up 8.8% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.15 EPS.

PGNY has been the topic of several other reports. Leerink Partners reduced their target price on Progyny from $25.00 to $21.00 and set a “market perform” rating on the stock in a research note on Thursday, September 19th. Truist Financial reduced their price objective on shares of Progyny from $33.00 to $26.00 and set a “buy” rating on the stock in a research report on Thursday, September 19th. BTIG Research cut shares of Progyny from a “buy” rating to a “neutral” rating in a research report on Wednesday, August 7th. JMP Securities lowered shares of Progyny from an “outperform” rating to a “market perform” rating in a research note on Thursday, September 19th. Finally, Canaccord Genuity Group downgraded shares of Progyny from a “buy” rating to a “hold” rating and decreased their price target for the stock from $37.00 to $24.00 in a research note on Wednesday, August 7th. Seven analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat.com, Progyny has a consensus rating of “Hold” and an average target price of $27.73.

Progyny Price Performance

Shares of NASDAQ:PGNY opened at $17.15 on Monday. The stock’s 50-day moving average is $23.59 and its 200 day moving average is $28.32. The company has a market cap of $1.63 billion, a PE ratio of 28.11, a P/E/G ratio of 1.97 and a beta of 1.45. Progyny has a 1 year low of $13.93 and a 1 year high of $42.08.

Insider Transactions at Progyny

In other news, Director Cheryl Scott sold 1,462 shares of the firm’s stock in a transaction on Friday, June 28th. The stock was sold at an average price of $28.39, for a total transaction of $41,506.18. Following the completion of the transaction, the director now directly owns 10,098 shares in the company, valued at $286,682.22. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, President Michael E. Sturmer sold 9,030 shares of the company’s stock in a transaction on Tuesday, July 16th. The stock was sold at an average price of $30.00, for a total transaction of $270,900.00. Following the transaction, the president now directly owns 362,583 shares of the company’s stock, valued at $10,877,490. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Cheryl Scott sold 1,462 shares of the company’s stock in a transaction dated Friday, June 28th. The shares were sold at an average price of $28.39, for a total transaction of $41,506.18. Following the transaction, the director now owns 10,098 shares in the company, valued at approximately $286,682.22. The disclosure for this sale can be found here. Insiders own 12.30% of the company’s stock.

Institutional Trading of Progyny

A number of large investors have recently made changes to their positions in the stock. Vanguard Group Inc. grew its holdings in shares of Progyny by 0.5% in the first quarter. Vanguard Group Inc. now owns 8,311,840 shares of the company’s stock worth $317,097,000 after acquiring an additional 41,687 shares during the period. Jennison Associates LLC grew its stake in shares of Progyny by 2.7% during the 1st quarter. Jennison Associates LLC now owns 2,596,422 shares of the company’s stock valued at $99,054,000 after purchasing an additional 67,632 shares during the period. Principal Financial Group Inc. grew its stake in shares of Progyny by 3.1% during the 1st quarter. Principal Financial Group Inc. now owns 1,400,701 shares of the company’s stock valued at $53,437,000 after purchasing an additional 42,302 shares during the period. Farallon Capital Management LLC increased its position in shares of Progyny by 120.8% during the 2nd quarter. Farallon Capital Management LLC now owns 1,308,500 shares of the company’s stock valued at $37,436,000 after purchasing an additional 715,900 shares during the last quarter. Finally, Dimensional Fund Advisors LP lifted its stake in shares of Progyny by 24.8% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,281,928 shares of the company’s stock worth $36,676,000 after purchasing an additional 254,725 shares during the period. 94.93% of the stock is currently owned by institutional investors.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.